Author

R. B. Riggins

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Organism:human· 8 Assay:bulk RNA-seq· 5 Research Focus:cell type annotation· 4 Research Focus:differential expression· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell signaling & trafficking· 3 Research Focus:drug response / drug discovery· 3

Frequent Co-Authors

D. M. Tiek· 3 shared S. Bahnassy· 3 shared A. Goenka· 2 shared B. Hu· 2 shared B. R. Haddad· 2 shared C. I. Wells· 2 shared D. L. Berry· 2 shared H. Stires· 2 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. M. Tiek

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Acquired temozolomide resistance instructs patterns of glioblastoma behavior in gelatin hydrogels

V. Kriuchkovskaia, E. Eames, R. B. Riggins, B. Harley

This paper develops a 3D hydrogel model to study how acquired temozolomide resistance affects glioblastoma cell behavior, showing changes in drug sensitivity, invasion, and cytokine production.

bioRxiv · Nov 14, 2023Bioengineering

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer

S. Bahnassy, H. Stires, L. Jin, S. Tam, D. Mobin, M. Balachandran, M. B. Podar, M. D. McCoy, R. A. Beckman, R. B. Riggins

The paper develops two in vitro models of endocrine therapy-resistant HER2+/ER+ breast cancer and identifies lipid metabolism and ferroptosis as therapeutic vulnerabilities.

bioRxiv · Aug 21, 2023Cancer Biology

SGC-CLK-1 (CAF-170) a chemical probe for the Cdc2-Like kinases CLK1, CLK2, and CLK4

D. Tiek, C. I. Wells, M. Schroder, X. Song, C. A. Ferrer, A. Goenka, R. Iglesia, M. Lu, B. Hu, F. Kwarcinski, P. Sintha, C. de Silva, M. A. Hossain, A. Picado, W. Zuercher, , D. Drewry

This paper identifies and characterizes SGC-CLK-1, a potent inhibitor of CLK1, CLK2, and CLK4, showing its selectivity and effects on SR protein phosphorylation and localization.

bioRxiv · Dec 15, 2022 · PreprintCancer Biology

WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers

J. L. Sottnik, M. T. Shackleford, F. R. Villagomez, S. Bahnassy, S. Oesterreich, J. Hu, Z. Madak-Erdogan, R. B. Riggins, B. R. Corr, L. S. Cook, L. S. Trevino, B. G. Bitler, M. J. Sikora

This study identifies WNT4's role in regulating cancer metabolism through mitochondrial intracellular signaling in breast and gynecologic cancers, linking genetic variants to metabolic remodeling.

bioRxiv · Jul 15, 2022Cancer Biology

Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug resistant gliomas

D. M. Tiek, B. Erdogdu, R. Razaghi, L. Jin, N. Sadowski, C. Alamillo-Ferrer, J. R. Hogg, B. R. Haddad, D. H. Drewry, C. I. Wells, J. E. Pickett, X. Song, A. Goenka, B. Hu, S. L. Goldlust, , R. B. Riggins

This study identifies guanine mutations in TMZ-resistant gliomas that disrupt G4 structures and splice sites, creating vulnerabilities targeted by G4 stabilizers and splicing inhibitors.

bioRxiv · Nov 21, 2021Cancer Biology

Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer

A. O. Olukoya, H. Stires, S. Bahnassy, S. Persaud, Y. Guerra, S. Ranjit, S. Ma, M. I. Cruz, C. Benitez, A. M. Rozeboom, H. Ceuleers, D. L. Berry, B. M. Jacobsen, G. V. Raj, R. B. Riggins

This study shows Riluzole reduces growth and improves response to endocrine therapy in ER+ breast cancer models.

bioRxiv · Jul 30, 2020 · PreprintCancer Biology

The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer

A. I. Fernandez, X. Geng, K. Chaldekas, B. Harris, A. Duttargi, V. L. Berry, D. L. Berry, A. Mahajan, L. R. Cavalli, B. Gyorffy, M. Tan, R. B. Riggins

This study examines the association of ESRRB mRNA, copy number, and protein expression with clinicopathological features in breast cancer specimens, finding reduced ESRRB expression and distinct isoform activity in TNBC/BLBC.

bioRxiv · Aug 13, 2019Cancer Biology

Estrogen-related receptor beta activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma

D. M. Tiek, S. A. Khatib, C. J. Trepicchio, M. M. Heckler, S. D. Divekar, J. N. Sarkaria, E. Glasgow, R. B. Riggins

This study shows that ERRβ2 isoform expression, increased by CLK inhibition and ERRβ agonists, reduces GBM cell migration and tumor growth.

bioRxiv · Apr 25, 2019Cancer Biology

Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma

D. M. Tiek, J. D. Rone, G. T. Graham, E. L. Pannkuk, B. R. Haddad, R. B. Riggins

This study creates and characterizes two new TMZ-resistant GBM cell lines, revealing distinct phenotypic changes associated with resistance.

bioRxiv · Dec 14, 2017Cancer Biology